# EVOLVE Short DAPT Study

> **NCT02605447** · PHASE4 · COMPLETED · sponsor: **Boston Scientific Corporation** · enrollment: 2009 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** 3 months of dual antiplatelet therapy (DAPT)
- **DEVICE:** SYNERGY Stent System

## Key facts

- **NCT ID:** NCT02605447
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-16
- **Primary completion:** 2019-07-17
- **Final completion:** 2019-07-17
- **Target enrollment:** 2009 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605447, "EVOLVE Short DAPT Study". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02605447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*